HILLEVAX INC. - COMMO

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 16:05:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

05 дек 2022 06:30:00 Источник Nasdaq GlobeNewswire

HilleVax to Participate in November Investor Conferences

10 ноя 2022 18:30:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

10 ноя 2022 16:05:01 Источник Nasdaq GlobeNewswire

HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

01 сен 2022 17:18:14 Источник Nasdaq GlobeNewswire

HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

31 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

15 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

10 авг 2022 16:01:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

20 июл 2022 16:05:00 Источник Nasdaq GlobeNewswire

HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

08 июн 2022 16:01:00 Источник Nasdaq GlobeNewswire

HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

03 май 2022 16:00:00 Источник Nasdaq GlobeNewswire